Peer Reviewed
Observation time on subsequent injections of subcutaneous daratumumab may be safely removed from institutional policies to reduce chair time.
Morgan Alvah, PharmD
Advertisement
Articles by Morgan Alvah, PharmD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pneumonic Plague: What Pharmacists Need to Know About Treatment
2
FDA Approves First Once-Monthly Subcutaneous Olanzapine LAI for Adults With Schizophrenia
3
FDA Approves Pritelivir for Refractory HSV Lesions in Immunocompromised Adults
4
Could Cemdisiran Keep Patients With Myasthenia Gravis Out of the Hospital?
5